Kellly Evans

BSTP-ESTP Congress
,

Kelly Evans is an Associate Director in Immunotoxicology at AstraZeneca. With over 10 years’ experience working with 3D in vitro models and new approach methodologies (NAMs), she develops and characterises human-relevant advanced cell models to assess drug-related immune safety risks. Prior to her current role, Kelly received her bachelor’s degree in Genetics from Cardiff University, during which time she began working with 3D culture systems, specifically intestinal organoids to study potential drug toxicity on the intestinal epithelium. Later, she obtained her PhD in Physiology, Development and Neuroscience from the University of Cambridge, where she established a human lung alveolar organoid system from primary adult stem cells that successfully modelled the effects of SARS-Cov-2 infection, highlighting the utility of advanced human cell models.